Table 1.
The characteristics of the twelve included studies.
| No. | First author, year | Country | Sample size | Glioma grade | Endpoint | Detection method | Cut-off |
|---|---|---|---|---|---|---|---|
| 1 | Tetsu Yamaki, 2020 (17) | Japan | 167 | IV | TTD and TTL | The integration of IHC with Western blot | Ratio>1 |
| 2 | Yasuo Iwadate, 2017 (15) | Japan | 70 | IV | PFS | IHC | 10% |
| 3 | Yasuo Iwadate, 2016 (14) | Japan | 80 | IV | PFS | IHC | 10% |
| 4 | Ichiyo Shibahara, 2015 (16) | Japan | 86 | III | TTD and TTL | The integration of IHC with Western blot | Ratio > 1 |
| 5 | Rikke H Dahlrot, 2014 (22) | Denmark | 211 | III and IV | PFS | Immunofluorescence | 2% |
| 6 | Jung Ha Shin, 2013 (23) | South Korea | 67 | IV | PFS | IHC | 50% |
| 7 | Ichiyo Shibahara, 2013 (19) | Japan | 112 | IV | TTD and TTL | The integration of IHC with Western blot | Ratio > 1 |
| 8 | Consolación Melguizo, 2012 (24) | Spain and Italy | 78 | IV | PFS | IHC | 25% |
| 9 | Kyung-Jung Kim, 2011 (25) | South Korea | 88 | IV | PFS | IHC | 50% |
| 10 | JIE HE, 2011 (26) | China | 59 | III and IV | PFS | IHC | 10% |
| 11 | Roberto Pallini, 2008 (27) | Italy | 44 | IV | PFS | Immunofluorescence | 2% |
| 12 | Felix Zeppernick, 2008 (28) | Germany | 24 | III | PFS | IHC | 1% |
TTD, time to distant recurrence; TTL, time to local recurrence; PFS, progression-free survival, and IHC, immunohistochemistry.